Share on StockTwits

Smith & Nephew plc (NYSE:SNN)‘s stock had its “buy” rating reiterated by equities researchers at Deutsche Bank in a research report issued on Friday.

Shares of Smith & Nephew plc (NYSE:SNN) traded down 0.32% on Friday, hitting $87.76. 90,089 shares of the company’s stock traded hands. Smith & Nephew plc has a one year low of $57.99 and a one year high of $100.90. The stock’s 50-day moving average is $89.01 and its 200-day moving average is $78.97. The company has a market cap of $15.674 billion and a price-to-earnings ratio of 28.22. Smith & Nephew plc also was the recipient of a significant increase in short interest in June. As of June 13th, there was short interest totalling 769,246 shares, an increase of 52.2% from the May 30th total of 505,437 shares. Based on an average daily trading volume, of 551,834 shares, the days-to-cover ratio is presently 1.4 days. Approximately 0.0% of the shares of the stock are short sold.

Smith & Nephew plc (NYSE:SNN) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.89 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.93 by $0.04. Analysts expect that Smith & Nephew plc will post $4.13 EPS for the current fiscal year.

SNN has been the subject of a number of other recent research reports. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Thursday. Separately, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Tuesday. Finally, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Tuesday, June 24th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Smith & Nephew plc presently has an average rating of “Buy” and an average target price of $97.00.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.